Strongbridge Biopharma PLC (NASDAQ:SBBP)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Wednesday. They currently have a $18.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 218.58% from the stock’s current price.
SBBP has been the topic of several other reports. Zacks Investment Research upgraded Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating and set a $7.25 price objective on the stock in a research note on Wednesday, October 11th. ValuEngine lowered Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $11.81.
Shares of Strongbridge Biopharma PLC (SBBP) traded up $0.25 on Wednesday, reaching $5.65. The company had a trading volume of 97,220 shares, compared to its average volume of 104,749. Strongbridge Biopharma PLC has a 1 year low of $2.00 and a 1 year high of $8.85. The company has a debt-to-equity ratio of 1.89, a quick ratio of 4.46 and a current ratio of 4.63.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $114,000. Rhumbline Advisers bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $154,000. California State Teachers Retirement System bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $277,000. Teachers Advisors LLC bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $331,000. Institutional investors and hedge funds own 56.53% of the company’s stock.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.